Welcome to our dedicated page for IPSEN SA S/ADR news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on IPSEN SA S/ADR stock.
IPSEN SA S/ADR (IPSEY) is a global biopharmaceutical company focused on transformative medicines in oncology, rare disease, and neuroscience. Recently, they have achieved Health Canada approval for Bylvay™ (odevixibat) for treating pruritus in patients with Progressive Familial Intrahepatic Cholestasis (PFIC). Bylvay is a non-systemic ileal bile acid transport inhibitor offering new hope for patients with PFIC. The company is involved in multiregional partnerships to expand access to innovative therapies globally.
On June 1, 2022, Ipsen announced a total volume of 11,500 shares traded with an average price of €94.2155 across three transactions. The issuer identification code is 549300M6SGDPB4Z94P11, and the financial instrument code is FR0010259150. Each day showed varying volumes; for example, 3,000 shares were traded at €94.2039 on June 1, 2022, while 4,500 shares exchanged at €94.1873 the next day.
Ipsen has appointed an investment-services provider to acquire 125,000 shares, representing approximately 0.15% of its share capital, over a three-month period. This purchase is aligned with the employee free share-allocation plan and was authorized by the Combined Shareholders’ meeting on May 24, 2022.
In FY 2021, Ipsen recorded Specialty Care sales of €2.6 billion, operating in over 100 countries. The company is recognized for its focus on Oncology, Rare Disease, and Neuroscience.
Ipsen (Euronext: IPN; ADR: IPSEY) has announced promising data on Cabometyx® (cabozantinib) to be presented at ASCO 2022, highlighting its efficacy across several cancer types including non-small cell lung cancer (NSCLC) and advanced renal cell carcinoma. The Phase Ib COSMIC-021 study showcases Cabometyx's potential in metastatic NSCLC when combined with atezolizumab. Results from the Phase III COSMIC-311 trial further affirm Cabometyx's effectiveness in treating radioactive iodine-refractory differentiated thyroid cancer. Overall, these findings underscore Cabometyx’s role as a significant treatment option.
The Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) approved all 20 resolutions, including a dividend payment of €1.20 per share, effective from 2 June 2022, with an ex-date of 31 May 2022. The meeting, chaired by Mr. Marc de Garidel, also appointed PricewaterhouseCoopers Audit as the new Statutory auditor, replacing Deloitte & Associés. Key discussions included the company's strategy and 2021 financial performance.
On May 24, 2022, IPSEN proposed a share repurchase program to its shareholders, requesting authorization to repurchase up to 10% of its total shares (approx. 8.4M shares). The program aims to enhance market liquidity, retain shares for potential mergers or employee stock plans, and possibly cancel acquired shares. The maximum repurchase price is set at €200 per share, with a theoretical total of €1.68 billion dedicated to this initiative over 18 months. This authorization will replace a prior 2021 approval.
Ipsen released an update regarding its share capital on 30 April 2022. The total number of shares is reported at 83,814,526, leading to a gross total of voting rights amounting to 132,068,424. The net total of voting rights, which excludes shares without voting rights, stands at 130,792,368. This information complies with the regulatory requirements set forth by the French Commercial Code and the Autorité des Marchés Financiers.
The Shareholders of Ipsen are invited to the Combined Shareholders’ Meeting on 24 May 2022 at 3:00 p.m. in Paris. Important resolutions include the approval of a €1.20 dividend per share for FY2021, with an ex-date of 31 May 2022 and payment on 2 June 2022. The meeting's preliminary notice was published on 15 April 2022, and final details will be available on Ipsen's website. The company remains focused on transformative medicines across Oncology, Rare Disease, and Neuroscience with €2.6bn in Specialty Care sales for FY2021.
Ipsen has received European Commission approval for Cabometyx (cabozantinib) as a monotherapy for adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) who are refractory to radioactive iodine. This approval is significant as it represents the first second-line treatment option in Europe for this rare cancer. Cabometyx showed a 78% reduction in risk of disease progression or death compared to placebo in the COSMIC-311 Phase III trial, confirming its efficacy. There are currently limited treatment options for patients in this category.
Ipsen (ADR: IPSEY) reported a strong Q1 2022 total sales performance of €687.9m, up 12.5% from the previous year, with core drivers including Decapeptyl, Dysport, Cabometyx, and Onivyde showing double-digit growth. However, Somatuline sales remained flat due to increased competition and generic market entries. The company confirmed its full-year guidance, anticipating total sales growth above 2% at constant exchange rates. Ipsen is in negotiations to divest its Consumer HealthCare business, expected to finalize by Q3 2022, further focusing on Specialty Care.
Ipsen announced the filing of its 2021 Universal Registration Document with the French Autorité des Marchés Financiers on 12 April 2022, registered under number D.22-0283. The document is available on ipsen.com and includes the Annual Financial Report and the Board of Directors’ Report on Corporate Governance. With total sales of €2.9bn in FY 2021, Ipsen specializes in transformative medicines across Oncology, Rare Disease, and Neuroscience, with operations in over 100 countries.
FAQ
What is the current stock price of IPSEN SA S/ADR (IPSEY)?
What is the market cap of IPSEN SA S/ADR (IPSEY)?
What is IPSEN SA S/ADR focused on?
What recent achievement has IPSEN SA S/ADR made?
What is Bylvay™ (odevixibat)?
What are IPSEN SA S/ADR's partnerships focused on?
